Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 27Neoplasm Metastasis 8Colonic Neoplasms 7Rectal Neoplasms 5Pancreatic Neoplasms 4Stomach Neoplasms 3Neoplasms 3Carcinoma, Neuroendocrine 2Pancreatic Adenocarcinoma Metastatic 1Metastatic Pancreatic Ductal Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1Margins of Excision 1Liver Metastasis Colon Cancer 1Gastroesophageal Adenocarcinoma 1CRC 1Advanced Gastric or EGJ Cancer 1Adenocarcinoma 1

Interventions

spartalizumab 1sapropterin 1penpulimab 1niraparib 1anlotinib 1Taxes 1Ipilimumab 1IFL protocol 1Gemcitabine 1Decitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Pancreatic Adenocarcinoma Metastatic × IFL protocol × Clear all
NCT06747845 2025-09-16

ParpVax2

Abramson Cancer Center at Penn Medicine

Phase 2 Recruiting
68 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡